Chronic Pain News and Research

RSS

Somatic Systems accelerates efforts on projects to provide pain care services to the US Military

Somatic Systems, Inc. (PINKSHEETS: SMAS) stated that they have accelerated their efforts on their projects to provide pain care services to the US Military and establish Military health insurance coverage for Somatic Systems' powerful Clinical Somatics pain treatment method.

15 Sep 2009

Dominion develops and validates clinical quantitative assays for tapentadol

Dominion Diagnostics (Dominion) has recently developed and validated one of the first clinical quantitative assays for the drug tapentadol (Nucynta(TM)) performed by liquid chromatography/tandem mass spectrometry (LC/MS/MS). Tapentadol, recently approved for use by the FDA, is a centrally-active analgesic that has demonstrated efficacy in pain relief with improved gastrointestinal tolerability compared to other opioids for pain management.

15 Sep 2009

Studies to focus on treatments for traumatic battlefield injuries

The University of Maryland R Adams Cowley Shock Trauma Center in Baltimore, Md., will serve as one of 12 core clinical centers in a newly established Extremity Trauma Clinical Research Consortium funded by the U.S. Department of Defense.

15 Sep 2009

Extremity Trauma Clinical Research Consortium for treating major limb injuries

The Johns Hopkins Bloomberg School of Public Health has been awarded $18.4 million by the Orthopaedic Extremity Trauma Research Program (OETRP) of the U.S. Department of Defense to establish an Extremity Trauma Clinical Research Consortium.

14 Sep 2009

University of Surrey lecturer on Co-sleeping

The event will be a series of overlapping presentations based on video clips of older people talking about their experience of poor sleep, and the impact this has on their lives. The presenters are all involved in the SomnIA (Sleep in Ageing) project based at the University of Surrey. As well as the video-based presentations and discussions, members of the audience will be invited to share some of their own experiences of poor sleep, and write down questions which they would like the panel of presenters to address during the last part of the event.

11 Sep 2009

Cymbalta maintains reduction in pain for patients with chronic low back pain

New data show patients with chronic low back pain on Cymbalta(R) (duloxetine HCl) maintained reductions in pain for 41 weeks. In patients who initially responded to duloxetine, this maintenance of pain reduction was accompanied by further reduction in pain that was statistically significant as measured by the Brief Pain Inventory (BPI) average pain rating.

11 Sep 2009

Campaign to educate customers on chronic pain management

VitalWear, Inc. (www.vitalwear.com), a leader in thermal compression medical devices announced that it is launching a Direct Mail and Web campaign in an effort to educate customers on a recent report from the Center for Disease Control (CDC), stating that among all diabetics, 52% suffer from arthritis.

11 Sep 2009

ORT remains underutilized in U.S. prison systems

Almost a quarter of a million individuals addicted to heroin are incarcerated in the United States each year. However, many prison systems across the country still do not offer medical treatment for heroin and opiate addiction, despite the demonstrated social, medical and economic benefits of opiate replacement therapy (ORT).

9 Sep 2009

First results of European survey of cancer patients' experience of breakthrough pain presented at EFIC

The first results of the first European survey of cancer patients' experience of breakthrough pain were presented today at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC).

9 Sep 2009

Advocacy campaign to fight reimbursement cuts for POC urine drug screen devices

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, has announced the launch of an advocacy campaign to fight reimbursement cuts to point-of-care (POC) urine drug screen devices.

9 Sep 2009

LTS LOHMANN Therapie-Systeme celebrates 25th anniversary

LTS LOHMANN Therapie-Systeme AG, the leading developer and manufacturer of transdermal, topical and oral systems with facilities in Andernach, Germany and West Caldwell, New Jersey, celebrates its 25th anniversary.

1 Sep 2009

Nutra Pharma’s Cobroxin pain reliever is "Best New Product" at the ECRM Conference

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its recently launched pain reliever, Cobroxin, was selected as the “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference. Cobroxin was chosen as the award recipient by conference attendees, including several of the leading national retailers.

31 Aug 2009

Cannabis Science enters into an agreement with Leading Points to represent its products to various government and military agencies

Cannabis Science Inc. (OTCBB: CBIS), an emerging pharmaceutical cannabis company is pleased to announce that the company has signed an agreement with Leading Points Corporation to represent its products, services and initiatives to various government and military agencies.

31 Aug 2009

DURECT signs agreement with King Pharmaceuticals to supply two excipients for REMOXY

DURECT Corporation (Nasdaq: DRRX) today reported that it has signed an exclusive long term excipient supply agreement with respect to REMOXY(R) with King Pharmaceuticals, Inc. (NYSE: KG). This agreement stipulates the terms and conditions under which DURECT will supply to King, based on DURECT's manufacturing cost plus a specified percentage mark-up, two key excipients used in the manufacture of REMOXY.

27 Aug 2009

Canadian Anesthesiologists' Society responds to reports on Michael Jackson's death

The Canadian Anesthesiologists' Society (CAS) represents the only trained physicians providing anesthetic services in Canada. CAS is responding to reports that Michael Jackson was given a fatal combination of drugs, including the powerful anesthetic propofol, prior to his death on June 25.

27 Aug 2009

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.

27 Aug 2009

Study confirms inappropriate use of pain medication among the chronic pain population

A study published in the August issue of the peer-reviewed journal Population Health Management revealed that the majority of patients prescribed opioids for chronic pain were unlikely to be taking their medicine in a manner consistent with their prescribed regimen. In the study, titled "Inappropriate Drug Use in the Chronic Pain Population," 938,586 urine toxicology tests conducted on over 500,000 patients prescribed chronic opioid therapy were analyzed using proprietary and state of the art screening methods offered by Ameritox(R).

27 Aug 2009

QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules

QRxPharma Limited and announced today successful completion of its pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients with moderate to severe pain following total knee replacement surgery.

27 Aug 2009

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Cobroxin, an over-the-counter (OTC) treatment for stage 2 (moderate to severe) chronic pain.

25 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

Chronic Pain News and Research

Somatic Systems accelerates efforts on projects to provide pain care services to the US Military

Dominion develops and validates clinical quantitative assays for tapentadol

Studies to focus on treatments for traumatic battlefield injuries

Extremity Trauma Clinical Research Consortium for treating major limb injuries

University of Surrey lecturer on Co-sleeping

Cymbalta maintains reduction in pain for patients with chronic low back pain

Campaign to educate customers on chronic pain management

ORT remains underutilized in U.S. prison systems

First results of European survey of cancer patients' experience of breakthrough pain presented at EFIC

Advocacy campaign to fight reimbursement cuts for POC urine drug screen devices

LTS LOHMANN Therapie-Systeme celebrates 25th anniversary

Nutra Pharma’s Cobroxin pain reliever is "Best New Product" at the ECRM Conference

Cannabis Science enters into an agreement with Leading Points to represent its products to various government and military agencies

DURECT signs agreement with King Pharmaceuticals to supply two excipients for REMOXY

Canadian Anesthesiologists' Society responds to reports on Michael Jackson's death

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

Study confirms inappropriate use of pain medication among the chronic pain population

QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News